[go: up one dir, main page]

WO2002083876A3 - Molecules secretoires - Google Patents

Molecules secretoires Download PDF

Info

Publication number
WO2002083876A3
WO2002083876A3 PCT/US2002/009921 US0209921W WO02083876A3 WO 2002083876 A3 WO2002083876 A3 WO 2002083876A3 US 0209921 W US0209921 W US 0209921W WO 02083876 A3 WO02083876 A3 WO 02083876A3
Authority
WO
WIPO (PCT)
Prior art keywords
sptm
provides
diagnostic assays
purified
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/009921
Other languages
English (en)
Other versions
WO2002083876A2 (fr
Inventor
Abel Daffo
Anissa L Jones
Alanna-Phung B Tran
Christopher R Dahl
Darryl Gietzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to AU2002311791A priority Critical patent/AU2002311791A1/en
Priority to CA002447212A priority patent/CA2447212A1/fr
Priority to EP02739118A priority patent/EP1409504A2/fr
Publication of WO2002083876A2 publication Critical patent/WO2002083876A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002083876A3 publication Critical patent/WO2002083876A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des polynucléotides sécrétoires purifiés (SPTM), ainsi que les polypeptides (SPTM) codés par ces SPTM. Cette invention concerne également l'utilisation de SPTM, ou de compléments, d'oligonucléotides ou encore de fragments de ces derniers dans des dosages diagnostiques. Cette invention se rapporte en outre à des vecteurs et des cellules hôtes contenant des SPTM pour l'expression de SPTM, à l'utilisation de SPTM isolés et purifiés pour induire des anticorps et cribler des bibliothèques de composés ainsi qu'à l'utilisation d'anticorps anti-SPTM dans des dosages diagnostiques. La présente invention concerne enfin des jeux ordonnés de microéchantillons contenant des SPTM et des méthodes d'utilisation.
PCT/US2002/009921 2001-03-29 2002-03-27 Molecules secretoires Ceased WO2002083876A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002311791A AU2002311791A1 (en) 2001-03-29 2002-03-27 Secretory molecules
CA002447212A CA2447212A1 (fr) 2001-03-29 2002-03-27 Molecules secretoires
EP02739118A EP1409504A2 (fr) 2001-03-29 2002-03-27 Molecules secretoires

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US28006701P 2001-03-29 2001-03-29
US28006801P 2001-03-29 2001-03-29
US60/280,068 2001-03-29
US60/280,067 2001-03-29
US29128001P 2001-05-16 2001-05-16
US60/291,280 2001-05-16
US29182901P 2001-05-17 2001-05-17
US29184901P 2001-05-17 2001-05-17
US60/291,849 2001-05-17
US60/291,829 2001-05-17
US29942801P 2001-06-19 2001-06-19
US60/299,428 2001-06-19
US30000101P 2001-06-20 2001-06-20
US29977601P 2001-06-20 2001-06-20
US60/300,001 2001-06-20
US60/299,776 2001-06-20

Publications (2)

Publication Number Publication Date
WO2002083876A2 WO2002083876A2 (fr) 2002-10-24
WO2002083876A3 true WO2002083876A3 (fr) 2004-02-19

Family

ID=27575326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009921 Ceased WO2002083876A2 (fr) 2001-03-29 2002-03-27 Molecules secretoires

Country Status (4)

Country Link
EP (1) EP1409504A2 (fr)
AU (1) AU2002311791A1 (fr)
CA (1) CA2447212A1 (fr)
WO (1) WO2002083876A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227008B2 (en) 1999-04-12 2007-06-05 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7309585B2 (en) 2001-03-05 2007-12-18 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
WO2003059948A1 (fr) * 2002-01-15 2003-07-24 Medigene Ag Gene-2 associe a la myocardiopathie dilatee (dcmag-2) : inducteur cytoplasmique du remodelage sarcomerique de cardiomyocytes
US7485709B2 (en) * 2002-05-31 2009-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of a novel BHD gene
GB0217033D0 (en) * 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2005003336A2 (fr) 2003-07-07 2005-01-13 Universiteit Utrecht Holding B.V. Choline-phosphotransferases et ethanolamine-phosphotransferases nouvellement identifiees
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP5572938B2 (ja) * 2007-10-25 2014-08-20 東レ株式会社 免疫誘導剤
EP2213301B1 (fr) 2007-10-25 2017-12-06 Toray Industries, Inc. Inducteur de la réponse immunitaire
US9249409B2 (en) * 2007-10-25 2016-02-02 Toray Industries, Inc. Method for detection of cancer
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 10 August 2000 (2000-08-10), "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", XP002964530, accession no. NCBI Database accession no. (BE552030) *
DATABASE GENBANK [online] 7 July 2000 (2000-07-07), WATERSON R.H.: "The sequence of homo sapiens clone", XP002964529, accession no. NCBI Database accession no. (AC023786) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227008B2 (en) 1999-04-12 2007-06-05 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7306796B2 (en) 1999-04-12 2007-12-11 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7309585B2 (en) 2001-03-05 2007-12-18 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers

Also Published As

Publication number Publication date
EP1409504A2 (fr) 2004-04-21
AU2002311791A1 (en) 2002-10-28
WO2002083876A2 (fr) 2002-10-24
CA2447212A1 (fr) 2002-10-24

Similar Documents

Publication Publication Date Title
WO2002097031A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004023973A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002083876A3 (fr) Molecules secretoires
WO2004092209A3 (fr) Antigenes s-pneumoniae
WO2000073509A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004078907A3 (fr) Antigenes vis-a-vis du streptococcus pyogenes
WO2001004264A3 (fr) Genes associes a l'atherosclerose
EP0897004A3 (fr) Histidyl tRNA synthétase issu de Streptococcus pneumoniae (hisS)
WO2005103073A3 (fr) Antigenes de lambliase (diarrhee des voyageurs)
WO2003020894A3 (fr) Facteur de transcription lie a l'insuline et utilisations de celui-ci
WO2002099080A3 (fr) Methodes de clonage d'adn, a faible pourcentage de clones negatifs, a l'aide d'oligonucleotides longs
WO2002046228A3 (fr) Recepteur de la toxine du b. anthracis
WO2001068859A3 (fr) Molecules du type recepteur de l'interleukine 17 et leur utilisation
WO2002020756A3 (fr) Molécules sécrétoires
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2002040715A8 (fr) Molecules permettant la detection et le traitement de maladies
WO2003062376A3 (fr) Molécules pour le diagnostic et la thérapeutique
WO2003062385A3 (fr) Molecules secretoires
WO2004094467A3 (fr) Antigenes h. pylori
WO2001062918A3 (fr) Molecules secretoires
WO2001062927A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001062922A3 (fr) Molecules destinees a la detection et au traitement de maladies
WO2002055738A3 (fr) Molecules pour la detection et le traitement de maladies
WO2002057304A3 (fr) Molecules secretrices
WO2002020754A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002739118

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2447212

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002739118

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002739118

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP